Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.36 |
| ▸ | DRD1 | P21728 | 5/20 | 0.36 |
| ▸ | DRD5 | P21918 | 5/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169024 | 1.00 | CTSS (0.36) | CTSSDRD1DRD5CTSKHSD11B1 | |
| SCHEMBL3174616 | 0.90 | CTSS (0.37) | CTSSDRD1DRD5CTSKHSD11B1 | |
| SCHEMBL3174620 | 0.90 | CTSS (0.37) | CTSSDRD1DRD5CTSKHSD11B1 | |
| SCHEMBL3178189 | 0.88 | DRD1 (0.38) | DRD1DRD5 | |
| SCHEMBL3178194 | 0.88 | DRD1 (0.38) | DRD1DRD5 | |
| SCHEMBL3179577 | 0.87 | DRD1 (0.44) | DRD1DRD5AVPR1A | |
| SCHEMBL3179574 | 0.87 | DRD1 (0.44) | DRD1DRD5AVPR1A | |
| SCHEMBL3175509 | 0.81 | PDE4B (0.37) | DRD1DRD5 | |
| SCHEMBL3175515 | 0.81 | PDE4B (0.37) | DRD1DRD5 | |
| SCHEMBL3183911 | 0.81 | PDE4B (0.37) | DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | claimed |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | PIGS, GPR174, GPR17 | CTSS 507/4885DRD1 1469/4885DRD5 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.